SecBot SecBot
8-K ·Filed May 5, 2026

PTGX

Protagonist Therapeutics, Inc
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001104659-26-055629
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The Q1 beat and $200M opt-out payment provide a strong financial base. Watch for rusfertide PDUFA in August 2026 and ICOTYDE commercial ramp. The stock may re-rate as revenue visibility improves.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$103.97
T+0 close · May 5, 2026 · via day close
Latest settled
+31.42%
T+60 · $136.64
Vs SPY
+29.36%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 6 $103.97entry
  2. T+1 · 6mo ago −4.92%α −4.59% · $98.85
  3. T+5 · 6mo ago −3.87%α −5.00% · $99.95
  4. T+20 · 6mo ago −8.23%α −11.01% · $95.41
  5. T+60 · 4mo ago +31.42%α +29.36% · $136.64

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Protagonist Therapeutics reported Q1 2026 revenue of $56.4M and GAAP EPS of $0.05, significantly exceeding consensus estimates of $16.3M and -$0.65. The beat was driven by a $50M milestone from ICOTYDE FDA approval and the rusfertide opt-out election triggering a $200M payment. The company turned profitable versus a year-ago loss, and cash runway extends through 2028, marking a major inflection point.

Key Financial Metrics

EPS
$0.05
est −$0.65 · +107.7%
Revenue
$56.4M
est $16.3M · +245.8% · +99.0% YoY
Rating
beat

Key Facts

  • Q1 2026 license and collaboration revenue $56.4M vs $28.3M YoY (99% increase)
  • Net income $3.8M vs net loss $11.7M YoY; basic EPS $0.06 vs -$0.19
  • ICOTYDE FDA approval triggered $50M milestone; rusfertide opt-out triggers $200M payment
  • Cash and marketable securities $620M as of March 31, 2026, providing runway through at least 2028

Financial Impact

Q1 2026 revenue $56.4M (beat consensus $16.3M by 246%), GAAP diluted EPS $0.05 (beat consensus -$0.65 by 108%)

revenueepscash

Risk Factors

  • Revenue heavily reliant on non-recurring milestones and partner payments
  • Rusfertide regulatory risk ahead of PDUFA (August 2026)
  • Dependence on J&J (ICOTYDE) and Takeda (rusfertide) for commercialization

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-055629
Document: tm2613550d1_8k.htm0001104659-26-055629
Document: 0001104659-26-055629-index-headers.html0001104659-26-055629
Document: 0001104659-26-055629-index.html0001104659-26-055629
Document: 0001104659-26-055629.txt0001104659-26-055629
8-K Data (Synthetic)0001104659-26-055629

Track record

11 reports on PTGX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 5, 202611d ago 8-K Bullish 7/10 Entry $132.04 Now $124.83 −5.46% settles Feb 4
  2. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $143.37 Now $124.83 −12.93% settles Feb 2
  3. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $142.14 Now $124.83 −12.18% settles Jan 26
  4. Aug 10, 202614w ago 144 Bearish 5/10 Entry $148.29 to $143.37 Now $124.83 +15.82% ▲ +3.32% +2.83% vs SPY
  5. Jun 18, 202621w ago 8-K Neutral 3/10 Entry $115.03 to $143.40 Now $124.83 +8.52% ▲ +24.66% +22.92% vs SPY
  6. Jun 12, 202622w ago Institutional Cluster Mixed 5/10 Entry $109.78 to $145.94 Now $124.83 +13.71% ▲ +32.94% +29.67% vs SPY
  7. May 12, 202626w ago 144 Bearish 5/10 Entry $103.88 to $145.87 Now $124.83 −20.17% ▼ −40.42% −35.98% vs SPY
  8. May 8, 202627w ago Insider Cluster Neutral 4/10 Entry $99.36 to $135.81 Now $124.83 +25.63% ▲ +36.68% +31.85% vs SPY
  9. May 8, 202627w ago Insider Cluster Neutral 5/10 Entry $99.36 to $135.81 Now $124.83 +25.63% ▲ +36.68% +31.85% vs SPY
  10. May 5, 202627w ago 8-K Bullish 7/10 Viewing Entry $103.97 to $136.64 Now $124.83 +20.06% ▲ +31.42% +29.36% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026